Skip to main content

BRIEF RESEARCH REPORT article

Front. Aging Neurosci.
Sec. Neuroinflammation and Neuropathy
Volume 16 - 2024 | doi: 10.3389/fnagi.2024.1507683

Aspirin Modulates Inflammatory Biomarkers in Patients with Subcortical Silent Brain Infarcts

Provisionally accepted
Wonjae Sung Wonjae Sung Yeong Seo Kim Yeong Seo Kim Kyu-Yong Lee Kyu-Yong Lee Hojin Choi Hojin Choi Young Joo Lee Young Joo Lee Seong-Ho Koh Seong-Ho Koh *
  • Hanyang University, Seoul, Republic of Korea

The final, formatted version of the article will be published soon.

    Introduction: This study aimed to identify differences in the levels of inflammation-related biomarkers between patients with subcortical silent brain infarcts (SBIs) and healthy controls.We also evaluated the effect of aspirin on the subcortical SBI inflammatory processes.Methods: Consecutive patients diagnosed with subcortical SBIs without a history of acute stroke were included. The demographic and clinical data of the 26 subjects with subcortical SBIs, such as the number and location of subcortical SBIs, were reviewed. Plasma levels of macrophage migration inhibitory factor (MIF), matrix metalloproteinase-9 (MMP-9), and visfatin were measured in patients with subcortical SBIs and ten healthy participants. These biomarkers were rechecked in patients with subcortical SBI three months after taking aspirin (100 mg/day).Results: MIF and MMP-9 levels were significantly higher in patients with subcortical SBIs than in healthy control group (p = 0.031 and p = 0.026, respectively). Although MIF and MMP-9 did not show significant changes after taking aspirin for three months, the median plasma level of visfatin was significantly decreased from 1.00 ng/mL (range, 0.86 -1.16 ng/mL) to 0.84 ng/mL (range, 0.77 -0.91 ng/mL) (p = 0.002) after taking aspirin.Discussion: Inflammation could be an essential factor in the pathogenesis of subcortical SBIs, and aspirin affects several inflammation-related biomarkers.

    Keywords: subcortical silent brain infarct, Aspirin, Inflammation, macrophage migration inhibitory factor, matrix metalloproteinase-9, visfatin Statements and Declarations

    Received: 08 Oct 2024; Accepted: 16 Dec 2024.

    Copyright: © 2024 Sung, Kim, Lee, Choi, Lee and Koh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Seong-Ho Koh, Hanyang University, Seoul, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.